Lingling S. Dong
Beijing Key Laboratory For Drug Resistant Tuberculosis Research
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Performance of stool-based Xpert MTB/RIF assay in the diagnosis of presumptive pulmonary tuberculosis in adults unable to expectorate sputum.
Journal: Microbiology spectrum
Published: February 25, 2025
Corrigendum to "Tuberculosis-targeted next-generation sequencing and machine learning: An ultrasensitive diagnostic strategy for paucibacillary pulmonary tuberculosis and tuberculous meningitis" [Clin. Chim. Acta 553 (2024) 117697].
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: May 10, 2024
In vitro antimicrobial activity of doxycycline, minocycline, and tigecycline against Mycobacterium abscessus complex: A meta-analysis study.
Journal: Diagnostic microbiology and infectious disease
Published: March 24, 2024
Tuberculosis-targeted next-generation sequencing and machine learning: An ultrasensitive diagnostic strategy for paucibacillary pulmonary tuberculosis and tuberculous meningitis.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: September 12, 2023
An early and trustable indicator suggestive of non-tuberculosis mycobacteria isolation in a high tuberculosis burden setting.
Journal: The Journal of infection
Published: September 07, 2023
Xpert MTB/RIF Ultra Assay Using Stool: an Effective Solution for Bacilli Identification from Adult Pulmonary Tuberculosis Suspects without Expectorated Sputum.
Journal: Microbiology spectrum
Published: June 28, 2023
In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria.
Journal: Microbiology spectrum
Published: December 08, 2022
Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients.
Journal: Journal of global antimicrobial resistance
Published: November 08, 2022
Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China.
Journal: Frontiers in medicine
Published: October 20, 2022
Nosiheptide Harbors Potent In Vitro and Intracellular Inhbitory Activities against Mycobacterium tuberculosis.
Journal: Microbiology spectrum
Published: October 12, 2022
Biological interpretation of the sporadic sputum smear-positive-culture-negative outcome for patients with tuberculosis undertaking treatments.
Journal: Frontiers in public health
Published: October 08, 2022
In vitro and Intracellular Antibacterial Activity of Sudapyridine (WX-081) Against Tuberculosis.
Journal: Infection and drug resistance
Published: September 17, 2022
Last Updated: 09/26/2026